Thesis Concerns over increasing competition and potential pricing pressures are overshadowing the positive developments in plasma collection capacity and regulatory approvals.
★ Analysts see FY2027 revenue reaching $8.1B — +6.0% growth in a single year.
What Moves the Stock 01 Changes in plasma collection volumes, particularly in the U.S. and Europe 02 Regulatory approvals for new therapies or indications 03 Pricing adjustments for existing therapies 04 Market demand for immunoglobulin therapies 05 Plasma-derived therapies (approximately 70% of total revenue) 06 Diagnostic products (approximately 20% of total revenue) 07 Other (approximately 10% of total revenue) 08 Growing demand for immunoglobulin therapies driven by increasing prevalence of autoimmune diseases 6.8 7.3 7.8 8.3 8.8 7.65 GRFS Daily 7.65 Apr '26 Jun '26 Jul '26 Sep '26
My Notes "Management noted, 'While we are expanding our collection capabilities, we must remain vigilant about pricing pressures from emerging competitors.'" Moat: Grifols' extensive network of plasma collection centers and established brand reputation provide a significant competitive advantage. value - Grifols' low price-to-sales ratio and strong cash flow generation appeal to value investors. Rising interest rates may increase Grifols' financing costs, impacting its ability to invest in expansion and R&D… Watch on earnings: Plasma collection volumes, Gross margin trends, Regulatory approval timelines for new therapies. One Sentence Summary: Grifols: the story is balanced — changes in plasma collection volumes, particularly in the u.s.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
